Intensity Therapeutics, Inc.

A clinical stage biotechnology company whose mission is to create safer and more efficacious cancer therapies.

General Information
Company Name
Intensity Therapeutics, Inc.
Founded Year
2012
Location (Offices)
Westport, United States +1
Founders / Decision Makers
Robert Cooke - Senior Vice President Lewis Bender - Founder and CEO
Number of Employees
13
Industries
Biopharma, Biotechnology, Health and Wellness
Funding Stage
Post Ipo Secondary
Social Media

Intensity Therapeutics, Inc. - Company Profile

Intensity Therapeutics, Inc. is a clinical stage biotechnology company with a mission to develop safer and more effective cancer therapies. The company utilizes its DfuseRxSM technology platform to create new drug formulations that disperse rapidly throughout a tumor and diffuse therapeutic agents into cancer cells, offering a new immune-based approach to treat solid tumor cancers. Their lead product candidate, INT230-6, is currently undergoing evaluation in a Phase 1/2 clinical study for various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor but also non-injected tumors and micro-metastases. Founded in 2012, the company is headquartered in Westport, Connecticut and operates in the Biopharma and Biotechnology industries. Intensity Therapeutics recently received a $2.80MPost-IPO Secondary investment on 26 March 2024. For more information, visit their website at www.intensitytherapeutics.com and follow them on Twitter at @IntensityInc.

Taxonomy: Cancer therapy, Immunotherapy, Drug formulation, Clinical-stage, Solid tumor cancers, Immune-based approach, Pharmaceuticals, Chemotherapy treatments, Intratumoral injection, Healthcare innovation, Clinical study, Adaptive immune response, Micro-metastases, Biopharmaceuticals

Funding Rounds & Investors of Intensity Therapeutics, Inc. (5)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Secondary $2.80M - 26 Mar 2024
Post-IPO Equity $19.50M - 29 Jun 2023
Series A $10.00M 5
Batterson Venture Capital, investor in Intensity Therapeutics, Inc.'s Series A round
Jim Mellon, SalvaRx Group PLC +2 		28 Jun 2016
Venture Round $500.00K - 12 Jun 2015
Venture Round $1.00M - 11 Feb 2014

Latest News of Intensity Therapeutics, Inc.

View All

No recent news or press coverage available for Intensity Therapeutics, Inc..

Similar Companies to Intensity Therapeutics, Inc.

View All
ImmunoGenesis, Inc. - Similar company to Intensity Therapeutics, Inc.
ImmunoGenesis, Inc. Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of immune resistance.
Huasaiboman Medical Cell Biology - Similar company to Intensity Therapeutics, Inc.
Huasaiboman Medical Cell Biology Pioneering tomorrow's treatments for solid tumors and degenerative diseases through state-of-the-art cell therapy solutions.
Imvax, Inc. - Similar company to Intensity Therapeutics, Inc.
Imvax, Inc. Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies.
Revitope - Similar company to Intensity Therapeutics, Inc.
Revitope Powered for Precision: Revolutionizing immunotherapy to safely and effectively treat more cancers
Cytovation - Similar company to Intensity Therapeutics, Inc.
Cytovation Creating transformative medicines for patients with cancer